Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 35
- 主要终点
- Percentage of Patients With Complete Clearing of Corneal Staining at Month 12
研究概览
简要总结
The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults >16 years of age
- •Dry eye patients
- •Subject with history of less than 12 weeks of initial RESTASIS® treatment
- •Subject started second trial of RESTASIS® treatment prior to June 1, 2008
- •First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment
排除标准
- •Patients with Contact Lens Intolerance
- •Patients with Ocular Rosacea
研究组 & 干预措施
Patients who received Restasis®
Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
干预措施: Cyclosporine Ophthalmic Emulsion 0.05% (Drug)
结局指标
主要结局
Percentage of Patients With Complete Clearing of Corneal Staining at Month 12
时间窗: Month 12
Percentage of patients with complete clearing of corneal staining at month 12. Corneal staining is evaluated following administration of fluorescein dye into the eye. Complete clearing is defined as the absence of corneal staining.
次要结局
- Schirmer's Test at Month 12(Month 12)